Plus Therapeutics, Inc. (Nasdaq: PSTV) announced today that it has entered into a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH) to provide access to its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory-developed test (LDT). This agreement extends coverage to more than 51 million UnitedHealthcare members across the United States, significantly broadening access to cutting-edge neuro-oncology diagnostics.

“This nationwide coverage agreement marks a pivotal step in expanding the availability of CNSide® testing to more patients and providers managing leptomeningeal metastases (LM),” said Plus Therapeutics CEO, Marc Hedrick M.D. “By partnering with UnitedHealthcare, we are driving wider adoption of precision diagnostics that can improve treatment monitoring and clinical decision-making.”

Advancing Precision Diagnostics for Leptomeningeal Metastases

CNSide® is a proprietary, highly sensitive CSF assay platform that delivers critical clinical insights for patients with leptomeningeal metastases and other central nervous system (CNS) cancers. The platform supports:

• Rapid & Accurate Diagnosis – Detecting tumor cells in the cerebrospinal fluid.
• Treatment Monitoring – Tracking response and disease progression over time.
• Therapy Guidance – Helping providers optimize personalized treatment plans.

By improving how clinicians detect, monitor, and treat LM, CNSide® empowers providers with actionable, real-time data that can enhance patient outcomes and inform clinical strategies.

Why This National Agreement Matters

• Expanded Patient Access — Over 51 million individuals nationwide may now have coverage for the CNSide® assay under UnitedHealthcare.
• Accelerated Adoption — Greater insurance support can drive increased utilization among oncologists and neuro-oncology specialists.
• Improved Care Pathways — Patients may benefit from earlier diagnosis and more precise treatment adjustments, potentially leading to better outcomes.

This milestone strengthens Plus Therapeutics’ position in the precision diagnostics market and aligns with the company’s mission to make advanced CNS cancer testing more widely accessible.

Learn More About CNSide® Diagnostics

About CNSide®: CNSide Diagnostics Official Website
Read the Full Announcement: Plus Therapeutics and UnitedHealthcare National Agreement
Investor Relations: Plus Therapeutics (Nasdaq: PSTV)

#CNSideDiagnostics #CNSide #LeptomeningealMetastases #PrecisionDiagnostics #NeuroOncology #PSTV #PlusTherapeutics #UnitedHealthcare #CSFAssay #LDT #HealthcareInnovation